Elimination of the nonionic contrast medium iopromide in end-stage renal failure by hemodialysis. 1989

H Kierdorf, and J Kindler, and R Winterscheid, and H J Hollmann, and D Vorwerk, and U Speck

The increasing life-expectancy of patients with end-stage renal failure has led to a significant increase of diagnostic and interventional radiologic measures. The contrast media used in these procedures, however, are excreted only very slowly, due to the renal failure. We have therefore studied the elimination of the nonionic x-ray contrast medium iopromide (Ultravist) during dialysis in nine anuric patients with end-stage renal failure. All of the patients received 100 ml iopromide (30 g iodine) for the visualization of their Cimino-Brescia shunt. They were then dialyzed 30 minutes after the injection. The plasma iodine concentration declined from 1.7 to 0.7 mg I/ml plasma during the 3-hour dialysis treatment. The iopromide clearance was a constant 80 ml/min. This is the equivalent of a relative dialysance of 65% of the creatinine clearance. There were no incidences of side effects requiring therapy in this high-risk group of patients. The quality of the image was good in all cases. Iopromide proved itself to be an x-ray contrast medium with a low rate of side effects, which can be effectively eliminated from the body by means of conventional dialysis.

UI MeSH Term Description Entries
D007472 Iohexol An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. Compound 545,Exypaque,Iohexol 350,Nycodenz,Omnipaque
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003287 Contrast Media Substances used to allow enhanced visualization of tissues. Radiopaque Media,Contrast Agent,Contrast Agents,Contrast Material,Contrast Materials,Radiocontrast Agent,Radiocontrast Agents,Radiocontrast Media,Agent, Contrast,Agent, Radiocontrast,Agents, Contrast,Agents, Radiocontrast,Material, Contrast,Materials, Contrast,Media, Contrast,Media, Radiocontrast,Media, Radiopaque
D005260 Female Females
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

H Kierdorf, and J Kindler, and R Winterscheid, and H J Hollmann, and D Vorwerk, and U Speck
January 1990, Nephron,
H Kierdorf, and J Kindler, and R Winterscheid, and H J Hollmann, and D Vorwerk, and U Speck
August 1984, Zeitschrift fur Urologie und Nephrologie,
H Kierdorf, and J Kindler, and R Winterscheid, and H J Hollmann, and D Vorwerk, and U Speck
January 1995, Nephron,
H Kierdorf, and J Kindler, and R Winterscheid, and H J Hollmann, and D Vorwerk, and U Speck
March 1975, Clinical pharmacology and therapeutics,
H Kierdorf, and J Kindler, and R Winterscheid, and H J Hollmann, and D Vorwerk, and U Speck
June 1970, Harefuah,
H Kierdorf, and J Kindler, and R Winterscheid, and H J Hollmann, and D Vorwerk, and U Speck
October 1999, Nihon Ika Daigaku zasshi,
H Kierdorf, and J Kindler, and R Winterscheid, and H J Hollmann, and D Vorwerk, and U Speck
January 2002, Deutsche medizinische Wochenschrift (1946),
H Kierdorf, and J Kindler, and R Winterscheid, and H J Hollmann, and D Vorwerk, and U Speck
December 1992, The British journal of radiology,
H Kierdorf, and J Kindler, and R Winterscheid, and H J Hollmann, and D Vorwerk, and U Speck
July 1980, The Journal of nursing care,
H Kierdorf, and J Kindler, and R Winterscheid, and H J Hollmann, and D Vorwerk, and U Speck
March 2018, Anesthesia and analgesia,
Copied contents to your clipboard!